Oxurion Pins Hopes On THR-149 After THR-687 Flops In DME

 
• By Alaric DeArment
  
Eye
Oxurion announced that the Phase II study of THR-687 showed insufficient efficacy on its key endpoints • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business